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Abstract
Introduction: Alterations in voltage-gated sodium channel (VGSC) function have been linked to chronic pain and
are good targets for analgesics. Lacosamide (LCM) is a novel anticonvulsant that enhances the slow inactivation
state of VGSCs. This conformational state can be induced by repeated neuronal firing and/or under conditions of
sustained membrane depolarisation, as is expected for hyperexcitable neurones in pathological conditions such as
epilepsy and neuropathy, and probably osteoarthritis (OA). In this study, therefore, we examined the antinociceptive
effect of LCM on spinal neuronal and behavioural measures of pain, in vivo, in a rat OA model.
Methods: OA was induced in Sprague Dawley rats by intraarticular injection of 2 mg of monosodium iodoacetate
(MIA). Sham rats received saline injections. Behavioural responses to mechanical and cooling stimulation of the
ipsilateral hind paw and hindlimb weight-bearing were recorded. In vivo electrophysiology experiments were
performed in anaesthetised MIA or sham rats, and we recorded the effects of spinal or systemic administration of
LCM on the evoked responses of dorsal horn neurones to electrical, mechanical (brush, von Frey, 2 to 60 g) and
heat (40°C to 50°C) stimulation of the peripheral receptive field. The effect of systemic LCM on nociceptive
behaviours was assessed.
Results: Behavioural hypersensitivity ipsilateral to knee injury was seen as a reduced paw withdrawal threshold to
mechanical stimulation, an increase in paw withdrawal frequency to cooling stimulation and hind limb weight-bearing
asymmetry in MIA-treated rats only. Spinal and systemic administration of LCM produced significant reductions of the
electrical Aβ- and C-fibre evoked neuronal responses and the mechanical and thermal evoked neuronal responses in
the MIA group only. Systemic administration of LCM significantly reversed the behavioural hypersensitive responses to
mechanical and cooling stimulation of the ipsilateral hind paw, but hind limb weight-bearing asymmetry was not
corrected.
Conclusions: Our in vivo electrophysiological results show that the inhibitory effects of LCM were MIA-dependent. This
suggests that, if used in OA patients, LCM may allow physiological transmission but suppress secondary hyperalgesia
and allodynia. The inhibitory effect on spinal neuronal firing aligned with analgesic efficacy on nociceptive behaviours
and suggests that LCM may still prove worthwhile for OA pain treatment and merits further clinical investigation.
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Osteoarthritis (OA) is a degenerative joint disease that is
most prevalent in the elderly, and it is the primary
source of disability and one of the largest health care
burdens in the Western world [1]. Given the trend to-
wards an increasing elderly and obese (excessive weight
is a risk factor) population, the socioeconomic cost of
OA is likely to rise.
OA is characterized by damage to the articular cartil-
age and subchondral bone, as well as episodic inflamma-
tion of the joint. Its clinical presentation is dominated by
pain in the area surrounding the joint and often in areas
distant to the affected joint (referred pain/secondary
hyperalgesia) [2-6]. Current analgesic regimens include
paracetamol, nonsteroidal anti-inflammatory drugs, opi-
oids, steroids and combinations thereof, but they are un-
satisfactory for many patients, due either to inadequate
pain relief and/or to intolerable side effects [7]; thus, a
large unmet clinical need remains. Therefore, unravel-
ling the pathological mechanisms underlying the pain
state is of major clinical importance in the development
of more clinically effective drugs.
The transmission of pain from the peripheral site of
injury, beyond the peripheral transducers, requires ac-
tivation of voltage-gated sodium channels (VGSCs) lo-
cated on peripheral nociceptors, and abundant data exist
showing that alterations in the functional activity, distri-
bution and density of VGSCs are critical for mediating
chronic pain in both animals and humans [8,9]. Current
health care guidelines do not recommend sodium channel
blockers for the treatment of OA pain; however, there is
strong evidence for abnormal firing in peripheral and
central neurones in the arthritic condition, which must in-
volve alterations in VGSCs [10-17], and a genetic muta-
tion in the encoding gene for the 1.7 sodium channel
subtype has been correlated with increased pain sensitivity
in OA patients [18]. Indeed, the lidocaine patch and
intraarticular injection of nonselective VGSC blockers has
been shown to provide pain relief in patients with OA
[19-21]; therefore, there is a rational basis for extending
their application to the OA pain state.
One strategy that is being explored is widening the ap-
plication of existing licensed anticonvulsants for the treat-
ment of chronic pain [22,23]. The reasons for this are
twofold. First, epilepsy and chronic pain share common
neuronal mechanisms of increased excitability, providing
a logical mechanistic basis, and anticonvulsant drugs with
sodium channel–blocking activity, such as carbamazepine
and phenytoin, have efficacy in chronic pain associated
with nerve injury [24], and it is thought that OA pain may
include a neuropathic component [25-28]. Second, pre-
clinical and patient data already exists with regards to to-
xicity and tolerability of the drug in the setting of epilepsy,
which could be built upon to improve clinical trials. One
such anticonvulsant of interest is lacosamide (LCM),
which is licensed for the treatment of partial onset sei-
zures. Despite a recent negative outcome in phase III trials
for the treatment postherpetic neuralgia (PHN) [22], the
potential for LCM in treating OA pain, and indeed other
types of chronic pain (including nerve injury pains other
than PHN), may still exist because there is an argument
that different sets of mechanisms may cause pain in neu-
ropathic pain patients and also anecdotal evidence of
neuropathic patients who respond to one analgesic over
another [29].
LCM is a novel drug that targets the slow, inactivated
state of VGSCs to promote time spent in the refractory
state and hence directly reduce neuronal firing rate. The
slow inactivation state of neurones is induced under con-
ditions of repetitive neuronal firing and/or under condi-
tions of slight or sustained membrane depolarisation. This
is likely to be the case for the OA condition because spon-
taneous and enhanced evoked activity of joint nociceptors
and dorsal horn neurones have been reported [10-17], as
has sensitisation of spinal nociceptive withdrawal reflexes
[30], indicating that the monosodium iodoacetate (MIA)
model is associated with hyperexcitability. Given the afo-
rementioned evidence for altered primary afferent activity
in this model and the fact that blocking sensory fibre in-
puts with local anaesthetics blocks OA pain [21], our aim
was to study the effects of LCM on spinal neuronal acti-
vity evoked from stimuli applied to the ipsilateral hind
paws of rats using in vivo electrophysiological techniques.
These techniques allow spinal nociceptive processing and
central sensitisation to be studied experimentally and pro-
vide information on suprathreshold responses, which are
likely to equate to high levels of pain transmission as re-
ported by patients, as compared with behavioural data on
the basis of which the analgesic effect of drugs on thresh-
old responses are generally measured. The effects of sys-
temic administration of LCM on behavioural measures of
hypersensitivity were also tested.
Methods
Sprague Dawley rats (Central Biological Services, University
College London, UK), weighing 130 to 150 g at the time
of model induction and 250 to 270 g at the time of in vivo
electrophysiology and behavioural pharmacology, were
employed for this study. All experimental procedures were
approved by the UK Home Office and were carried out
in accordance with the guidelines of the International
Association for the Study of Pain [31].
Induction of osteoarthritis
On day 0, isoflurane-anaesthetised Sprague Dawley rats
weighing 130 to 150 g received an intra-articular in-
jection of 2 mg of MIA in 25 μl of 0.9% saline through
the infrapatellar ligament of the knee. Sham animals
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the injections, the animals were allowed to recover and
then were rehoused in cages under a 12-hour alternating
light–dark cycle with ad libitum access to food and
water. Animal welfare was monitored over the 2-week
period after model induction, with mobility and weight
gain seen to be normal.
Assessment of pain-related behaviour
Animals were habituated to the test environment for at
least 30 minutes prior to model induction and behavioural
testing. Behavioural assessment of hypersensitivity was
carried out on day 7 and day 14 postinjection. The asses-
sor was blinded to the model and treatment for the ani-
mals used in the behavioural pharmacology study, but not
for the animals used in the in vivo electrophysiology study;
however, here, quantification and recording of neurones
provide an entirely objective measure, as does the effect of
the drug on these measures.
Hind limb weight-bearing
Changes in hind paw weight-bearing were measured
using an incapacitance tester (Linton Instrumentation,
Norfolk, UK). Animals were placed in a Perspex (poly
(methyl methacrylate)) chamber designed to keep the
animal upstanding while the hind paws rest on a sepa-
rate small electronic balance so that the weight distri-
buted on the right and left hind paws can be measured.
Once the animal was settled, three consecutive readings
(each measured over 3 seconds) were recorded. The
average of a total of three readings was determined for
each hind limb for each rat and used for subsequent
analyses. The weight-bearing of the ipsilateral hind paw
to knee injection is presented as a percentage of the total
weight-bearing of both hind limbs.
Development of mechanical and cooling hypersensitivity
Behavioural responses to stimulation of the ipsilateral
hind paw were recorded once the animals had acclima-
tized to the testing area (Perspex cages with a wire mesh
floor) for at least 30 minutes. Tactile hypersensitivity
was tested by touching the plantar surface of the hind
paw with von Frey (vF) filaments (Touch-Test; North
Coast Medical, Gilroy, CA, USA) using the ‘up–down
method’ [32], starting with 2.0 g then ranging from 0.4 g
to 15 g. A cutoff of 15 g was set. Positive withdrawals
were counted as biting, licking and withdrawal during or
immediately following the stimulus. The strength of the
vF filament was increased or decreased following a nega-
tive or positive response, respectively. This up–down
procedure was applied four times following the first
change in response. Data are presented as 50% paw with-
drawal threshold (PWT) for each group±standard error
of the mean (SEM). Sensitivity to cooling stimulation was
assessed as the number of withdrawals out of a trial of five
applications of a drop of acetone to the plantar surface
of the ipsilateral hind paw. Withdrawal frequency was
quantified and presented as a percentage of the maximal
response calculated as (number of foot withdrawals/5
trials)×100.
Pharmacological studies
In vivo electrophysiology
Twenty-four animals were used in this study, with 12
allocated per group (sham or MIA injection). Two weeks
after MIA or sham injection, in vivo electrophysiological
studies were performed (post-MIA injection days 15 and
16) as previously described [33]. Briefly, animals were
initially anaesthetised with isoflurane (4%) delivered in a
gaseous mix of N2O (66%) and O2 (33%). A laminec-
tomy was then performed with the animals under iso-
flurane anaesthesia of 2% to 3% to expose the L4-L5
segment of the spinal cord. Anaesthetic levels of 1.5% to
1.7% were maintained for the duration of the experiment.
Extracellular recordings were taken from ipsilateral deep
dorsal horn neurones (lamina V-VI) using parylene-coated
Tungsten electrodes (A-M Systems, Carlsborg, WA,
USA). All the neurones recorded in this study were wide
dynamic range neurones, because they all responded to
both light touch and noxious inputs (pinch and noxious
heat). Furthermore, all neurones responded to natural
stimuli in a graded manner with coding of increasing
intensity.
The evoked response to a train of 16 transcutaneous
electrical stimuli (2-millisecond-wide pulses, 0.5 Hz)
applied at three times the threshold current for C-fibre
activation of the dorsal horn cell. The train of electrical
stimuli was delivered via stimulating needles inserted into
the peripheral receptive field, following which a post-
stimulus histogram was constructed. Responses evoked by
Aʲ- (0 to 20 milliseconds), Aʴ- (20 to 90 milliseconds)
and C-fibres (90 to 350 milliseconds) were separated and
quantified on the basis of latency. Responses occurring
after the C-fibre latency band were taken to be the post-
discharge of the cells (350 to 800 milliseconds). Two other
measures of electrically evoked neuronal activity were
made. One was the ‘input’, which is calculated as the
number of action potentials evoked by the first stimulus
(due to incoming C-fibre activity) in the train of electrical
stimuli response multiplied by 16. Thus,‘input’ is a meas-
ure of the nonpotentiated response—that is, the baseline
C-fibre-evoked response, which is likely a measure of af-
ferent input and the resultant spinal neuronal response
prior to central neuronal hyperexcitability evoked by
subsequent stimuli. We also measured ‘wind-up’,w h i c hi s
calculated as the total number of action potentials evoked
by C-fibre activity, minus the input. This potentiated re-
sponse, seen as increased neuronal activity in response to
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poral summation and central sensitisation. The centre of
the peripheral receptive field was also stimulated using
mechanical punctate and thermal stimuli (vF filaments, 2,
8, 26 and 60 g; and heat, applied with a constant water jet,
40°C, 45°C and 48°C). Application of each vF hair was sep-
arated by a minimum interval period of 5 to 10 seconds,
and longer for very responsive neurones at the higher in-
tensity range. Application of each subsequent heat stimu-
lus was separated by a minimum period of 1 minute. All
natural stimuli were applied for a period of 10 seconds per
stimulus. Data were captured and analysed by a CED
Power1401 interface coupled to a Pentium micropro-
cessor with Spike2 software (PSTH and rate functions;
Cambridge Electronic Design, Cambridge, UK). The data
for the vF forces are expressed on a linear scale because
the aim was to investigate drug effects on different inten-
sities of stimuli.
Pharmacological assessment was carried out on only
one neurone per animal. The testing procedure was car-
ried out every 20 minutes and consisted of a train of elec-
trical stimuli followed by natural stimuli as described
above. Following three consecutive stable control trials
(<10% variation for the C-fibre-evoked response and <20%
variation for all other parameters), neuronal responses
were averaged to give the predrug control values. LCM
was then administered either via topical spinal application
(10, 50 and 100 μg/50 μl) or systemically via subcutaneous
injection into the scruff of the neck (3 and 30 mg/kg). The
effect of each dose was followed for 1 hour, with tests car-
ried out at 10, 30 and 50 minutes before the next dose
was applied cumulatively.
Behaviour
Twenty animals were employed in this study; five ani-
mals received an intra-articular injection of saline and
fifteen received MIA. Development of behaviour was
assessed on days 7 and 14 postinjection, when animals
were randomly allocated to a Perspex chamber, and, fol-
lowing a 30-minute acclimatization period in the testing
room, baseline predrug behaviour was recorded as de-
scribed above, with the assessor blinded to the model.
Only animals that received MIA injections developed
significant behavioural hypersensitivity and were used to
study the effects of vehicle or LCM injection. Animals
received an intraperitoneal injection of saline (vehicle)
or 3 or 30 mg/kg LCM (n= 5 per group) and randomly
allocated to a Perspex chamber. The experimenter was
blinded to the injections. Behavioural tests were per-
formed at 30 and 60 minutes postinjection, always
following the same sequence for each batch of ex-
periments: acetone tests for all rats in order would be in-
terspersed in the interval between each PWT, that is,
acetone test rats 1−x, PWT rat 1, acetone test rats 1−x,
PWT rat 2 and so forth. Animals were then placed in the
incapacitance tester, and hind limb weight-bearing was re-
corded as detailed above.
Statistical analysis
All statistical tests were performed on raw data using
SPSS v22 software (IBM, Armonk, NY, USA). All data are
presented as mean±SEM. For in vivo electrophysiology
measurements, statistical significance was tested using a
nonparametric Mann-Whitney U test to compare two
groups of data, and a one-way or two-way repeated-
measures analysis of variance (RM-ANOVA), followed by
Bonferroni-corrected paired t-tests, was performed when
simultaneously comparing more than two groups of data.
Drug effects were measured as the maximum percentage
change from the averaged predrug control values for each
dose on each measure per neurone. The overall effect of
the drug (raw value) was then expressed and presented as
the mean maximal evoked neuronal response for each
dose. A one-way RM-ANOVA was used to evaluate drug
effects on the neuronal responses evoked by electrical and
dynamic brush stimulation, and a two-way RM-ANOVA
was used to evaluate drug effects on the neuronal re-
sponses evoked by mechanical or heat stimulation in MIA
or control rats. Behavioural data were analysed using the
Mann-Whitney U test to compare two groups of data; to
compare more than two groups of data, the Kruskal-
Wallis test, followed by Dunn’s posttest, was used. Values
of P<0.05 were considered significant.
Results
Development of behavioural hypersensitivity after
monosodium iodoacetate injection
Hypersensitivity to mechanical and cooling stimuli (akin
to allodynia) was observed in the MIA group. This was
seen as a significant decrease in the ipsilateral PWT in the
MIA group (Figure 1a). In addition, a significant increase
in the frequency of paw withdrawals to cooling stimula-
tion was seen in MIA rats compared with the same stimu-
lation of the ipsilateral hind paw in sham controls, which
elicited few, if any, hind limb withdrawals (Figure 1b).
A shift in hind paw weight-bearing was observed in the
MIA group, with less weight distributed onto the right
osteoarthritic limb compared with the left (contralateral)
hind limb. In comparison, the distribution of weight in the
sham control rats was largely equal over both hind limbs,
indicating the presence of ongoing joint discomfort and/
or pain in the MIA rats only (Figure 1c).
In vivo electrophysiology-evoked responses of dorsal horn
neurones
The effect of LCM delivered via a spinal or systemic
route was assessed upon the evoked responses of deep
dorsal horn (lamina V-VI) neurones to electrical and
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Comparison of the average baseline predrug responses for
MIA and shams per route of administration (spinal or
systemic) revealed a significantly greater Aʲ-fibre- and
brush-evoked response in the MIA versus sham animals
in the ‘spinal’ study (P< 0.05 by Mann-Whitney U test)
(Figures 2a to 2d), but a significantly greater postdischarge
in the sham group versus the MIA group (P<0. 05 b y
Mann-Whitney U test) (Figures 2a and 2b). However, no
significant difference was seen with any of the electrical or
brush-evoked responses in the ‘systemic’ study (P>0. 05
Mann-Whitney U test) (Figures 3a to 3d). No significant
difference was seen between the vF- and heat-evoked re-
sponse in MIA versus sham rats in either study (P>0. 05
by two-way ANOVA with Bonferroni posttest) (Figures 2e
though 2h and Figures 3e through 3h). The relatively
small sample size of neurones per group and per route of
administration means that the mean can on occasion be
shifted dramatically. Furthermore, as the present study
was not powered to compare baseline neuronal responses
between the MIA and sham groups, any differences in the
average baseline neuronal responses were not further ana-
lysed or emphasized. It should be noted, however, that
when we have previously characterized a large number of
cells we observed, on average, greater firing of neurones in
response to mechanical and thermal stimulation in the
MIA group, but not to electrical or brush stimuli [15].
Effects of spinal administration of lacosamide
Topical spinal application of LCM produced a dose-
related inhibition of a number of electrical and natural
evoked neuronal responses. LCM inhibited the Aʲ-A ʴ-
and C-fibre-evoked neuronal responses in the MIA group
only. In addition, LCM produced a dose-dependent inhib-
ition of the input measure of neuronal activity (Figure 2b),
which is suggestive of actions on afferent activity as well
as spinal transmission. Marked inhibitions of the natural
evoked responses in the MIA group were seen, with all
three doses producing an equivalent degree of significant
inhibition of the neuronal response to brush stimulation
(Figure 2d) and the neuronal response evoked by 60 g
stimulation (Figure 2f). The evoked responses to 8 and
26 g were inhibited by only the top two doses of LCM
(50 and 100 μg) (Figure 2f). LCM inhibited the evoked re-
sponse to noxious heat stimulation at 45°C and 48°C,
whereas the response evoked by innocuous heat stimula-
tion (40°C) of the hind paw was not affected by LCM at
any dose level (Figure 2h).
LCM produced minor inhibitions of some of the elec-
trical (Figure 2a) and natural mechanical and thermal
(Figures 2e and 2f) evoked neuronal responses in the
sham control group. For instance, the top dose of LCM
(100 μg) did produce a reduction of the evoked neuronal
response to vF 26 g and 48°C heat in some of the sham
sham MIA
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Figure 1 Behavioural assessment at day 14 after monosodium
iodoacetate (n= 27) or saline injection (n=17). Monosodium
iodoacetate (MIA injection) into the knee resulted in behavioural
hypersensitivity, compared with the sham controls that received
saline injections, as evidenced by the significant reduction in the
paw withdrawal threshold to mechanical punctate stimulation
(a), an increased paw withdrawal frequency to acetone application
(b) and a decrease in the amount of weight borne on the hind
limb ipsilateral to injection (c).* P< 0.05 compared with shams by
Mann-Whitney U test. Values are means±SEM.
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nificance compared with the mean predrug baseline
neuronal response.
Effects of systemic administration of lacosamide
Systemic administration of LCM reduced the overall neur-
onal response evoked by Aʲ- and C-fibre activity in the
MIA group; all other measures of neuronal excitability
and total neuronal response attributed to Aʴ-fibres were
resistant to LCM’s inhibitory effects (Figure 3b). Similarly
to the ‘spinal LCM’ group, significant inhibitions of the
evoked neuronal responses to brush, mechanical (8 to 60 g)
and thermal (45°C and 48°C) stimulation were seen with 3
and 30 mg/kg LCM in the MIA group (Figures 3d, 3f
and 3h). In complete contrast, LCM at these doses had no
significant effect on any neuronal measure in the sham
control group (Figures 3a, 3c, 3e and 3g).
Effects of systemic lacosamide on behavioural measures of
hypersensitivity
LCM at 3 and 30 mg/kg reversed some of the behavioural
measures of hypersensitivity seen in the MIA group com-
pared with the vehicle-treated group. Treatment with
LCM at 30 mg/kg significantly increased the PWT of the
arthritic hind paw from 1.4±0.4 g to 7.4±2.3 g (Figure 4a).
Treatment with the lower dose of LCM (3 mg/kg) pro-
duced some reversal of mechanical allodynia, but this did
not reach significance overall (Figure 4a). LCM at both
doses significantly reduced the paw withdrawal frequency
to cooling stimulation of the hind paw compared with
vehicle effect (Figure 4b). In contrast, ongoing joint dis-
comfort and/or pain, as measured by hind limb weight-
bearing, was not significantly improved by LCM at these
doses (Figure 4c).
Discussion
OA is a complex disease of the whole joint and typically
includes destruction and degradation of the articular
cartilage, subchondral bone, synovial lining and connec-
tive tissues [34]. Injection of MIA into the intraarticular
space of the knee joint mimics many of the pathological
signs of clinical OA, is associated with hyperexcitability
[10-17,27,30] and is a well-established model for the
study of osteoarthritic pain mechanisms that has also
been pharmacologically validated with respect to estab-
lished analgesics [35-37]. Histological assessment of the
knee joint was not assessed in the present study; however,
we have previously demonstrated knee joint pathology
seen as cartilage loss, which is characteristic of human
OA, with 2 mg of MIA [27], in accord with reports by
others [26,37,38]. In the present study, MIA injection pro-
duced weight-bearing asymmetry and hypersensitivity of
the ipsilateral hind paw, reflecting referred pain (secondary
hyperalgesia and central sensitisation), which confirms OA
pain development [39,40]. Although pain symptoms in
knee OA patients are mostly associated with the area sur-
rounding the affected joint, referred pain and tenderness
also occur, implying that mechanisms of central sensitisa-
tion contribute to the pain experience [2-6]. Evidence de-
rived from knee OA patients suggests that central
sensitisation is an important contributor to chronic OA
pain, and a direct link between the level of sensitisation in
referred areas and clinical pain intensity experienced by
OA patients has been shown [41]. Therefore, the data
presented here provide an electrophysiological and be-
havioural correlate for the spread of sensitisation seen in
OA patients and allows for the study of spinal nociceptive
processing and central sensitisation mechanisms.
There is good evidence that referred pain and central
sensitisation generally rely on afferent drives [5,42,43].
Thus, there is a logical basis for targeting this, and central
neuronal excitability, by blocking sodium channel function
to reduce action potential generation and transmission.
LCM is a nonselective drug in terms of its sodium channel
profile; however, it exerts ‘selective’ actions by enhancing
only the slow inactivation of VGSCs, unlike other sodium
channel–blocking drugs that bind to the fast inactivation
state (where classical antiepileptic drugs act) [44,45]. The
slow inactivation state of VGSCs can be induced by re-
peated neuronal firing and/or under conditions of slight
or sustained membrane depolarisation, as is the case for
neurones in pathological conditions such as epilepsy and
neuropathy [44,46]. So, too, it is probable for OA because
an increased incidence of spontaneous activity and
(See figure on previous page.)
Figure 2 Comparison of the effects of spinal administration of lacosamide and monosodium iodoacetate. These graphs show the effects
of lacosamide (LCM; 10, 50 and 100 ʼg) on the evoked neuronal responses to electrical (a, b), dynamic brush (c, d), mechanical punctate (e, f)
and thermal stimulation (g, h) of the peripheral receptive field in sham rats (n=6, left panel) and monosodium iodoacetate (MIA) rats (n=7, right
panel). The neuronal responses evoked by Aβ-, Aʴ- and C-fibres and the input measure of neuronal excitability, dynamic brush, von Frey (vF) 8 to
60 g and 45°C to 48°C heat stimulation were significantly reduced by LCM in the MIA group. LCM did not produce any significant effect on any
neuronal measure in the sham group. Asterisks and bars denote statistically significant main effects (one-way repeated-measures analysis of variance
(RM-ANOVA)). § denotes significance at 10 ʼg, + denotes significance at 50 ʼg and * denotes significance at 100 ʼg compared with baseline control
data (P< 0.05 by one-way RM-ANOVA with Bonferroni-corrected paired t-test). Values are mean±SEM. PD, Postdischarge; Input, Baseline C-fibre-evoked
response measure of afferent input and the resultant spinal neuronal response prior to central neuronal hyperexcitability evoked by subsequent stimuli;
W, Wind-up, a frequency-dependent incremental increase in neuronal response to repetitive stimulation of C-fibres (that is, a measure of central
neuronal hyperexcitability).
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horn neurones have been reported [10-17].
Our in vivo electrophysiological results show that the in-
hibitory effects of LCM are MIA state-dependent; that is,
the presence of OA favours recruitment of the slow in-
activated state of VGSCs because the drug had minimal
effects in the sham animals at these doses. This further
suggests that, if used in patients, LCM may allow physio-
logical transmission, yet attenuate abnormal pathophysio-
logical transmission. This is a key point because drugs
such as lidocaine have to be given locally to avoid interac-
tions with cardiac and neuronal function, but if, as the
data suggest, LCM has preferential effects only on the
mechanisms behind the OA pain, then oral administration
is possible.
LCM reduced firing to a wide range of mechanical and
thermal stimuli, when given both spinally and systemi-
cally, suggestive of a generalised state of abnormal sensi-
tivity within the area of referred pain. It is not possible
to ascertain if the drug effect occurs via reduced activity
in the inflamed knee afferents and/or more directly on
the abnormal spinal neurones. The latter action is sup-
ported by the ability of spinal administration of LCM to
attenuate the responses, indicating that a proportion of
the effect of the drug occurs via spinal actions on
VGSCs located on central terminals of primary afferents
and/or second-order neuronal networks.
Importantly, LCM not only acted to reduce spinal
neuronal firing but also normalised the reduced mech-
anical thresholds induced by MIA in the behavioural
studies. Systemic administration of LCM at 30 mg/kg
significantly reversed the hypersensitive response to
mechanical and cooling stimulation of the hind paw, in
line with the inhibitory effects of this dose on the mech-
anical punctate and brush-evoked neuronal responses in
the MIA group. The lowest dose of LCM (3 mg/kg) pro-
duced some reversal of the mechanical hypersensitive
response, but this did not reach significance, which con-
trasts with the significant inhibition in the mechanical
evoked neuronal response. This disparity between the
electrophysiological data and the behavioural outcome
may be explained by the fact that the level of neuronal
activity remaining after LCM treatment (3 mg/kg) is still
sufficient to elicit a behavioural response. It is interesting
to note that LCM, via both routes of administration, was
able to inhibit the electrically evoked Aʲ-fibre- and dy-
namic brush-evoked response in the MIA group only,
suggesting that LCM would likely be effective against
tactile allodynia in OA, which fits well with the effects of
LCM on the mechanical hypersensitive response seen in
the present study. Alterations in the electrophysiological
properties of Aʲ-fibre low-threshold mechanoreceptors
have been reported in a surgically induced model of OA
[47]. This may reflect a change in sodium currents in
these afferents and could underlie the preferential effect
of LCM on Aʲ-fibre-evoked responses in the MIA rats
in the present study.
It has previously been shown that systemic administra-
tion of 30 mg/kg LCM can reverse secondary tactile
allodynia [48]; however, the researchers in that earlier
study only observed significant effects of LCM in MIA
rats at days 3 and 7 after arthritis induction, and not on
day 14, which contrasts with our findings. This discre-
pancy is explicable by the fact that vehicle injection pro-
duced a much greater increase in the PWT in the study
by Beyreuther et al. [48], thus ‘masking’ any effect of
LCM at that particular time point. They did, however,
observe a significant antinociceptive effect of 3 and 30
mg/kg LCM on mechanical hyperalgesia at day 14 after
arthritis induction, which compares well with the potent
inhibition produced by systemic LCM of the suprathres-
hold mechanical (vF 26 and 60 g) evoked neuronal re-
sponses that we observed.
In contrast to the effects of the drug on mechanical
hypersensitivity, LCM at both doses completely reversed
the behavioural hypersensitive response to cooling sti-
mulation, suggesting greater analgesic efficacy against cold
allodynia. However, weight-bearing asymmetry was un-
affected. This may indicate a lack of effect on ongoing
pain or insufficient sensitivity of this commonly used
measure. It is clear that LCM is able to modulate both
threshold and suprathreshold responses to a range of na-
tural stimuli, but, importantly, a lack of effect on weight-
bearing does not preclude efficacy on other measures.
The observed selectivity of LCM for the MIA group
may reflect an enhanced and selective responsiveness of
(See figure on previous page.)
Figure 3 Comparison of the effects of systemic administration of lacosamide and monosodium iodoacetate. These graphs show the
effects of lacosamide (LCM; 3 and 30 mg/kg) on the evoked neuronal responses to electrical (a, b), dynamic brush (c, d), mechanical punctate
(e, f) and thermal stimulation (g, h) of the peripheral receptive field in sham rats (n=6, left panel) and monosodium iodoacetate (MIA) rats
(n=5, right panel). Neuronal responses evoked by Aβ- and C-fibres, dynamic brush, von Frey (vF) 8 to 60 g and 45°C to 48°C heat stimulation were
significantly reduced by LCM in the MIA group only. Asterisks and bars denote statistically significant main effect (one-way repeated-measures analysis
of variance (RM-ANOVA)). § denotes significance at 3 mg/kg, and * denotes significance at 30 mg/kg, compared with baseline control data (P<0. 05
by one-way RM-ANOVA with Bonferroni-corrected paired t-test). Values are mean±SEM. PD, Postdischarge; Input, Baseline C-fibre-evoked response
measure of afferent input and the resultant spinal neuronal response prior to central neuronal hyperexcitability evoked by subsequent stimuli;
W, Wind-up, a frequency-dependent incremental increase in neuronal response to repetitive stimulation of C-fibres (that is, a measure of central
neuronal hyperexcitability).
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arthritic condition, possibly due to increases in sodium
channel expression [49] and/or a greater proportion of
sodium channels in the conformational state favoured by
LCM (that is, slow inactivation) [44]. This model of
MIA-induced OA has features consistent with neur-
opathy, including upregulation of the neuronal damage
marker cAMP-dependent transcription factor (ATF-3) in
peripheral nerves that innervate the knee joint, as well
as alterations in spinal cord neuroimmune cells [25-28].
Furthermore, ectopic activity within injured nerves has
been demonstrated in both patients and rats [50-53].
Therefore, it is possible that ectopic activity of nocicep-
tors in and around the OA knee joint is a source of sus-
tained pain referral and central sensitisation seen in the
MIA rats. Indeed, a greater incidence of spontaneous ac-
tivity and increased firing frequency in joint-associated
primary afferents has been demonstrated, as well as a
greater excitability of deep dorsal horn neurones in MIA
rats [10-12,14-17]. Taken together, this means that there
is a far greater probability that the VGSCs present on af-
ferent nerves in the MIA group are in the slow inacti-
vated state, as compared with the sham control group,
thus providing the functional basis for the ‘selective’
actions of LCM in targeting the nociceptive neuronal
activity in the MIA group only.
LCM produced a significant and profound dose-
dependent inhibition of many electrophysiological and be-
havioural measures of nociception after spinal or systemic
administration in MIA animals. These findings align with
t h o s ep r e v i o u s l yr e p o r t e db yB e y r e u t h e ret al. [48] and may
predict analgesic efficacy in OA pain patients. However,
these preclinical findings for LCM in models of OA pain
have not positively translated to the clinic. Interestingly,
the assay sensitivity of randomised controlled trials has
been called into question [54]. If, for instance, the pharma-
cological sensitivity of OA patients with neuropathic fea-
tures differs from that of other OA patients, it might
explain LCM’s poor performance in clinical trials for OA
in a heterogeneous population [28]. The link between dis-
ease severity and neuropathic elements to the pain suggests
that the analgesic efficacy of LCM should be reassessed in
clinical trials enriched with OA patients with neuropathic
pain signs and symptoms. Indeed, if OA patient hetero-
geneity could be assessed in a manner similar to that de-
signed by the German Research Network on Neuropathic
Pain and grouped into phenotypically distinct subsets [55],
then this may provide a better outcome for LCM in treat-
ing OA pain. Independently of putative neuropathy, study
of OA patients with signs of central sensitisation and
spreading pain could be equally informative because this
c o u l db ed r i v e nb yo n g o i n gp e r i p h e r a lf i r i n g .I nl i n ew i t h
this hypothesis, a recent clinical trial demonstrated anal-
gesic efficacy of oxcarbamazepine, another sodium channel
blocker, in a subgroup of neuropathic patients following
patient stratification according to pain phenotype [56]. The
drug was effective in patients with ‘irritable nociceptors’,
and this phenotype could be present in OA patients, even
those without neuropathy.
Conclusion
LCM significantly inhibited neuronal responses only in
the MIA group, suggesting that changes in VGSC function
play a key role in mediating the neuroplasticity seen in the
OA pain state. The inhibitory effect on spinal neuronal fir-
ing aligned with the observed analgesic efficacy on beha-
vioural measures of pain suggest that LCM may still prove
worthwhile for the treatment of OA pain and merits fur-
ther clinical investigation. The findings of the present
study add to the large body of evidence demonstrating the
importance of alterations in VGSC activity in mediating
different chronic pain states and therefore advocates the
continued development and evaluation of novel sodium
channel–blocking drugs for the treatment of OA pain.
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